

ASX Release
18 January 2022

DIRECTOR APPOINTMENT – Mr Paul Jenz

- **Mr Jenz to join Compumedics Board as a non-executive director**
- **Mr Jenz brings significant capital market experience to the Board and will strengthen the interface with current and future shareholders**
- **Mr Jenz brings significant strategic and analytical skills to the board**

Compumedics Limited (ASX: CMP) (“Compumedics”) is pleased to announce that its current Board of Directors has unanimously agreed to the appointment of Mr. Paul Jenz as a Director of the Company, effective immediately, subject to shareholder approval at the Company’s next General Meeting.

Mr Jenz’s brings significant experience which will allow him to assist the Compumedics board across several key areas including corporate strategy; healthcare networks; emerging companies and their potential interface with Compumedics; finance; and Australian/Asian/Nth American capital markets. Mr Jenz is an accomplished investment banker and analyst having covered large capital market leaders (CSL, Cochlear, Sonic Healthcare, Ramsay Healthcare, ResMed etc) and in recent years he has focused on emerging MedTech ASX leaders.

Mr Jenz is currently Executive Director at PAC Partners Securities, a specialist corporate broker focused on matching emerging companies, which have a sustainable global advantage, with institutional investors. Mr Jenz is also Executive Chairman of the Agfood Fund, which is an unlisted unit trust investing across the agribusiness and food supply chain sectors.

“We are delighted to have Paul join the Board,” said Dr. David Burton, Executive Chairman and CEO at Compumedics. “He is a very experienced capital market executive who will bring considerable strategic and analytical experience to the Compumedics Board.”

“Paul has extensive experience in capital markets and strategic analysis, which are key to Compumedics on-going future success, both locally and in our main global markets.”

Paul joins the board at a very important time with key opportunities not only for the core business but also as it relates to breakout business opportunities including MEG and Somfit projects.” said Dr Burton. “Paul’s contact networks, strategic and analytical focus, and credentials in relation to capital markets and major strategic deals can potentially contribute to Compumedics value moving forward.”

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a medical device company involved in the development, manufacture, and commercialisation of diagnostics technology for the sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns US based Neuroscan, and Germany based DWL Elektronische GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia's Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian governments.

For further information please contact:**Dr. David Burton****Executive Chairman, CEO****P:** +61 3 8420 7300**F:** +61 3 8420 7399**David Lawson****Director, CFO****P:** + 61 3 8420 7300**F:** +61 3 8420 7399**Rod North**, Managing Director**Bourse Communications Pty Ltd****T:** +61 3 9510 8309, **M:** 0408 670 706**E:** rod@boursecommunications.com.au**Authorised for lodgement by Compumedics Limited's Board of Directors**